ADITUM BIO MANAGEMENT COMPANY, LLC
ADITUM BIO MANAGEMENT COMPANY, LLC is a Pre-seed, Seed, Series A, Series B, Series C+ and other fund in the US and Asia writing $100K–$20M checks into Healthcare, drug-development and healthcare-tech.
- Stages
- Pre-seed, Seed, Series A, Series B, Series C+, other
- Sectors
- Healthcare, drug-development, healthcare-tech
- Check size
- $100K–$20M
- Invests in
- US-wide, Asia
- Round role
- Leads rounds
- Actively investing
- Yes
- Founded
- 2019
- Assets under management
- $9B
- Website
- aditumbio.com
Thesis
Headquartered in Oakland, California, the firm employs a unique company-creation model to rapidly translate scientific discoveries into innovative medicines. They acquire preclinical assets and spin them into standalone biotech companies, guiding them through translational, Phase 1, and Phase 2 development. Aditum Bio invests across pre-seed, seed, Series A, Series B, and growth equity stages, often acting as a lead investor with an operator-led strategy. Their geographic focus is primarily the United States, with asset acquisition also pursued internationally, particularly in Asia. The firm is deploying capital from its third fund ($428 million), with total AUM exceeding $9 billion as of July 2025. Their minimum check size is $100,000 and the maximum is $20 million.
Common questions
Does ADITUM BIO MANAGEMENT COMPANY, LLC invest at the Pre-seed stage?
Yes. ADITUM BIO MANAGEMENT COMPANY, LLC lists Pre-seed, Seed, Series A, Series B, Series C+ and other among the stages it invests in.
What check size does ADITUM BIO MANAGEMENT COMPANY, LLC write?
ADITUM BIO MANAGEMENT COMPANY, LLC writes $100K–$20M checks.
Where does ADITUM BIO MANAGEMENT COMPANY, LLC invest?
ADITUM BIO MANAGEMENT COMPANY, LLC invests in the US and Asia.